{Reference Type}: Journal Article
{Title}: Preclinical efficacy of peanut-specific IgG4 antibody therapeutic IGNX001.
{Author}: Croote D;Wong JJW;Creeks P;Aruva V;Landers JJ;Kwok M;Jama Z;Hamilton RG;Santos AF;O'Konek JJ;Ferrini R;Thomas GR;Lowman HB;
{Journal}: J Allergy Clin Immunol
{Volume}: 0
{Issue}: 0
{Year}: 2024 Jul 26
{Factor}: 14.29
{DOI}: 10.1016/j.jaci.2024.07.014
{Abstract}: <B>BACKGROUND: </B>Existing therapeutic strategies are challenged by long times to achieve effect and often require frequent administration. Peanut-allergic individuals would benefit from a therapeutic that provides rapid protection against accidental exposure within days of administration while carrying little risk of adverse reactions.<BR><B>OBJECTIVE: </B>Guided by the repertoire of human IgE mAbs from allergic individuals, we sought to develop a treatment approach leveraging the known protective effects of allergen-specific IgG4 antibodies.<BR><B>METHODS: </B>We applied our single-cell RNA-sequencing SEQ SIFTER platform (IgGenix, Inc, South San Francisco, Calif) to whole blood samples from peanut-allergic individuals to discover IgE mAbs. These were then class-switched by replacing the IgE constant region with IgG4 while retaining the allergen-specific variable regions. In vitro mast cell activation tests, basophil activation tests, ELISAs, and an in vivo peanut allergy mouse model were used to evaluate the specificity, affinity, and activity of these recombinant IgG4 mAbs.<BR><B>RESULTS: </B>We determined that human peanut-specific IgE mAbs predominantly target immunodominant epitopes on Ara h 2 and Ara h 6 and that recombinant IgG4 mAbs effectively block these epitopes. IGNX001, a mixture of 2 such high-affinity IgG4 mAbs, provided robust protection against peanut-mediated mast cell activation in vitro as well as against anaphylaxis upon intragastric peanut challenge in a peanut allergy mouse model.<BR><B>CONCLUSIONS: </B>We developed a peanut-specific IgG4 antibody therapeutic with convincing preclinical efficacy starting from a large repertoire of human IgE mAbs from demographically and geographically diverse individuals. These results warrant further clinical investigation of IGNX001 and underscore the opportunity for the application of this therapeutic development strategy in other food and environmental allergies.